| Peer Recovery & Therapy Services, Llc | |
|
10 Hale St Fl 4 Charleston WV 25301-2830 | |
| (304) 544-5453 | |
| (304) 841-0688 |
| Full Name | Peer Recovery & Therapy Services, Llc |
|---|---|
| Speciality | Community/Behavioral Health |
| Location | 10 Hale St Fl 4, Charleston, West Virginia |
| Authorized Official Name and Position | Matthew Nelson (OWNER) |
| Authorized Official Contact | 3045511266 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Peer Recovery & Therapy Services, Llc 10 Hale St Fl 4 Charleston WV 25301-2830 Ph: (304) 544-5453 | Peer Recovery & Therapy Services, Llc 10 Hale St Fl 4 Charleston WV 25301-2830 Ph: (304) 544-5453 |
| NPI Number | 1568114262 |
|---|---|
| Provider Enumeration Date | 01/24/2022 |
| Last Update Date | 03/23/2022 |
| Certification Date | 03/23/2022 |
| Medicare PECOS PAC ID | 0244612083 |
|---|---|
| Medicare Enrollment ID | O20220727000244 |
News Archive
So-called type-3 secretion systems of pathogenic bacteria may be a suitable point of attack for future antibiotics. This is shown by Professor Maria Fällman and her associates at Umeå University in Sweden in the Proceeding of the National Academy of Sciences, PNAS, in the US.
A research team led by Seattle Children's Research Institute has discovered new gene mutations associated with markedly enlarged brain size, or megalencephaly.
Researchers have identified a master network of signaling molecules that acts like a "fuse box" to regulate the cellular effects of defective energy flow in mitochondrial respiratory chain diseases—a diverse set of difficult-to-treat genetic-based energy disorders.
Early on in the COVID-19 pandemic, azithromycin was regarded as being a potentially highly effective drug against the virus that causes it, SARS-CoV-2.
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568114262 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 251S00000X | Community/behavioral Health | (* (Not Available)) | Primary |
| 261QR0800X | Clinic/center - Recovery Care | (* (Not Available)) | Secondary |
| Provider Name | Mary Katherine Lilly |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1285013888 PECOS PAC ID: 8820302565 Enrollment ID: I20150807015400 |
News Archive
So-called type-3 secretion systems of pathogenic bacteria may be a suitable point of attack for future antibiotics. This is shown by Professor Maria Fällman and her associates at Umeå University in Sweden in the Proceeding of the National Academy of Sciences, PNAS, in the US.
A research team led by Seattle Children's Research Institute has discovered new gene mutations associated with markedly enlarged brain size, or megalencephaly.
Researchers have identified a master network of signaling molecules that acts like a "fuse box" to regulate the cellular effects of defective energy flow in mitochondrial respiratory chain diseases—a diverse set of difficult-to-treat genetic-based energy disorders.
Early on in the COVID-19 pandemic, azithromycin was regarded as being a potentially highly effective drug against the virus that causes it, SARS-CoV-2.
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
› Verified 2 days ago
| Provider Name | Brittany Leanne Henderson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1740830504 PECOS PAC ID: 2961888326 Enrollment ID: I20221007002806 |
News Archive
So-called type-3 secretion systems of pathogenic bacteria may be a suitable point of attack for future antibiotics. This is shown by Professor Maria Fällman and her associates at Umeå University in Sweden in the Proceeding of the National Academy of Sciences, PNAS, in the US.
A research team led by Seattle Children's Research Institute has discovered new gene mutations associated with markedly enlarged brain size, or megalencephaly.
Researchers have identified a master network of signaling molecules that acts like a "fuse box" to regulate the cellular effects of defective energy flow in mitochondrial respiratory chain diseases—a diverse set of difficult-to-treat genetic-based energy disorders.
Early on in the COVID-19 pandemic, azithromycin was regarded as being a potentially highly effective drug against the virus that causes it, SARS-CoV-2.
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
› Verified 2 days ago
News Archive
So-called type-3 secretion systems of pathogenic bacteria may be a suitable point of attack for future antibiotics. This is shown by Professor Maria Fällman and her associates at Umeå University in Sweden in the Proceeding of the National Academy of Sciences, PNAS, in the US.
A research team led by Seattle Children's Research Institute has discovered new gene mutations associated with markedly enlarged brain size, or megalencephaly.
Researchers have identified a master network of signaling molecules that acts like a "fuse box" to regulate the cellular effects of defective energy flow in mitochondrial respiratory chain diseases—a diverse set of difficult-to-treat genetic-based energy disorders.
Early on in the COVID-19 pandemic, azithromycin was regarded as being a potentially highly effective drug against the virus that causes it, SARS-CoV-2.
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
› Verified 2 days ago
Harmony Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1027 Quarrier St, Charleston, WV 25301 Phone: 681-265-9126 | |
Oasis, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 100 Peyton Way, Charleston, WV 25309 Phone: 304-720-8466 Fax: 304-720-8463 | |
Camc Family Resource Center Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 800 Pennsylvania Ave, Family Resource Center, Charleston, WV 25302 Phone: 304-388-1596 Fax: 304-388-2781 | |
Community Growth Behavioral Health Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 602 Virginia St E Ste 100, Charleston, WV 25301 Phone: 704-361-1999 | |
Linda S Geronilla Phd Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 92 Cook Dr, Charleston, WV 25314 Phone: 304-342-2260 Fax: 304-344-4522 | |
Wise Path Recovery Centers-charleston Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4701 Maccorkle Ave Se, Charleston, WV 25304 Phone: 304-503-3448 | |
Randy L Warren Md Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4501 Maccorkle Ave Sw, Suite 202, Charleston, WV 25309 Phone: 304-766-6666 Fax: 304-766-0999 |